| P50 | author | Patrick Vallance | Q29643725 |
| | James M Leiper | Q57240812 |
| P2093 | author name string | Douglas G Johns | |
| | Christine Y Ivashchenko | |
| | Benjamin T Bradley | |
| | Zhaohui Ao | |
| P2860 | cites work | Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases | Q22010563 |
| | Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase | Q24674431 |
| | Nitric oxide: physiology, pathophysiology, and pharmacology | Q26778243 |
| | Disruption of methylarginine metabolism impairs vascular homeostasis | Q27643718 |
| | LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases | Q28141381 |
| | Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression | Q28243109 |
| | Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation | Q28581627 |
| | Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling | Q28592810 |
| | Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in de | Q31102407 |
| | Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis | Q31155014 |
| | Biological significance of endogenous methylarginines that inhibit nitric oxide synthases | Q33847583 |
| | Does ADMA cause endothelial dysfunction? | Q34025837 |
| | Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase | Q34145182 |
| | Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence | Q34279059 |
| | Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease | Q34448784 |
| | Endothelial dysfunction: a marker of atherosclerotic risk | Q35067247 |
| | Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity | Q35190437 |
| | The DDAH/ADMA/NOS pathway | Q35603929 |
| | NO and angiogenesis | Q35603936 |
| | Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials | Q36381000 |
| | ADMA metabolism and clearance | Q36381017 |
| | Effects of atorvastatin on the different phases of atherogenesis | Q36957799 |
| | Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems | Q36969795 |
| | Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease | Q37305333 |
| | Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells | Q38314611 |
| | Selective binding of sterol regulatory element-binding protein isoforms and co-regulatory proteins to promoters for lipid metabolic genes in liver | Q38868474 |
| | Detrimental effect of oxidized LDL on endothelial arginine metabolism and transportation | Q40037358 |
| | Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery | Q40201959 |
| | Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia. | Q40333234 |
| | Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats | Q40386037 |
| | all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. | Q40736951 |
| | Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. | Q42451252 |
| | Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia | Q42452412 |
| | HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide | Q42505831 |
| | Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg | Q43594273 |
| | Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. | Q43850038 |
| | Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography | Q43957084 |
| | Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin | Q44283328 |
| | Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors | Q44291364 |
| | The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). | Q44294174 |
| | Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase | Q44477052 |
| | Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia | Q46362005 |
| | Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice | Q46375385 |
| | Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension | Q46626286 |
| | Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure | Q46631449 |
| | Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. | Q46761285 |
| | Resolution of apoptosis in atherosclerotic plaque by dietary modification and statin therapy. | Q46837713 |
| | Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure | Q46861533 |
| | Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. | Q46862730 |
| | Macrophage infiltration, lectin-like oxidized-LDL receptor-1, and monocyte chemoattractant protein-1 are reduced by chronic HMG-CoA reductase inhibition | Q46877195 |
| | Statin treatment and 3' polyadenylation of eNOS mRNA. | Q46966122 |
| | Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects. | Q46976526 |
| | Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins | Q46983709 |
| | Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins | Q47663251 |
| | Simvastatin improves diabetes-induced coronary endothelial dysfunction. | Q53784220 |
| | Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. | Q54301756 |
| | Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes. | Q54565890 |
| | Isolation and Identification of N,N- and N,N' -Dimethylarginine, Nε-Mono-, Di-, and Trimethyllysine, and Glucosylgalactosyl- and Galactosyl-δ-hydroxylysine from Human Urine | Q71575094 |
| | Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms | Q71659408 |
| | Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor | Q71698825 |
| | Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney | Q73961045 |
| | Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine | Q74332688 |
| | Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2 | Q80547912 |
| | Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO | Q80731355 |
| P433 | issue | 1 | |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | H251-8 | |
| P577 | publication date | 2009-11-13 | |
| P1433 | published in | American Journal of Physiology Heart and Circulatory Physiology | Q3193662 |
| P1476 | title | Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2. | |
| P478 | volume | 298 | |